CN110680905A - Application of TSLP in preparation of medicine for treating lumbar disc herniation - Google Patents
Application of TSLP in preparation of medicine for treating lumbar disc herniation Download PDFInfo
- Publication number
- CN110680905A CN110680905A CN201911016907.6A CN201911016907A CN110680905A CN 110680905 A CN110680905 A CN 110680905A CN 201911016907 A CN201911016907 A CN 201911016907A CN 110680905 A CN110680905 A CN 110680905A
- Authority
- CN
- China
- Prior art keywords
- tslp
- expression
- tgf
- beta
- jak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 title claims abstract description 51
- 206010050296 Intervertebral disc protrusion Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 title claims abstract 6
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 230000008569 process Effects 0.000 abstract description 10
- 210000002540 macrophage Anatomy 0.000 abstract description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 5
- 238000001764 infiltration Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 abstract description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 32
- 102000004889 Interleukin-6 Human genes 0.000 description 29
- 108090001005 Interleukin-6 Proteins 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 21
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 19
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 19
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 102000042838 JAK family Human genes 0.000 description 11
- 108091082332 JAK family Proteins 0.000 description 11
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 10
- 108010057466 NF-kappa B Proteins 0.000 description 10
- 102000003945 NF-kappa B Human genes 0.000 description 10
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 10
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 9
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 8
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000009103 reabsorption Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 5
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102000057208 Smad2 Human genes 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108700032504 Smad2 Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000009646 cryomilling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of TSLP in preparation of a medicament for treating lumbar disc herniation. TSLP can promote infiltration of macrophages into disc tissues by inducing the expression of monocyte chemotactic factor-1 (MCP-1) to be increased, thereby promoting the resorption process of the herniated lumbar disc tissues.
Description
Technical Field
The invention relates to the field of medical research, in particular to application of TSLP in preparation of a medicament for treating lumbar disc herniation.
Background
Lumbar disc herniation refers to rupture of nucleus pulposus from the intervertebral disc caused by degenerative change of the lumbar disc or fiber rupture caused by trauma, and presses lumbar nerves, so that the lumbar disc herniation causes the symptom of the radiation pain, and is called as lumbar disc herniation. Currently, only a few patients with prolapse type intervertebral disc and prolapse of lumbar intervertebral disc, whose conservative treatment symptoms are not relieved, receive surgical treatment. Studies by Shujohn et al have shown that the herniated disc tissue can heal itself through a resorption process, but the underlying mechanism is not yet clear. The Wangzhi and Yuan Hu propose that macrophage infiltration participates in the process of reabsorption, so that the protruded intervertebral disc tissue can be obviously reduced. This may be associated with macrophage-mediated release of several factors, including Matrix Metalloproteinases (MMPs) and Vascular Endothelial Growth Factor (VEGF).
Thymic Stromal Lymphopoietin (TSLP) is an IL-7-like cytokine found in the supernatant of mouse thymus stromal cells by Friend et al in 1994, and is secreted mainly by non-hematopoietic cells, such as fibroblasts, epithelial cells, stromal cells, and the like. TSLP mRNA is mainly expressed in epithelial cells, stromal cells and mast cells of tissues such as thymus, lung, skin, small intestine, etc., and is closely related to asthma and airway allergic inflammatory reaction. Moret et al found that TSLP plays an important role in rheumatoid arthritis; koyama et al demonstrated increased expression of TSLP in vitro experimental studies of synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis, suggesting that TSLP is also expressed in bone tissue and involved in inflammatory responses. Ohba et al have demonstrated that TSLP is also expressed in mouse and human disc tissues, and that tumor necrosis factor-alpha (TNF-alpha) can up-regulate the expression of TSLP in vitro experiments by nuclear factor-kappa B (NF-kappa B), while TSLP can cause macrophage infiltration into disc tissues by promoting the expression of monocyte chemotactic factor-1 (MCP-1) and increased expression of TSLP is also found in disc tissues of patients with disc herniation, and TSLP is considered to be an important factor in mediating resorption. However, it is still unknown whether the body up-regulates the expression of TSLP and how to regulate TSLP after herniated disc.
Disclosure of Invention
The invention aims to provide application of TSLP in preparation of a medicament for treating lumbar disc herniation.
In a previous study, the applicant found that when the inflammatory environment of lumbar disc herniation is simulated by stimulating mouse disc tissues with the inflammatory factor TNF-alpha, an increase in TSLP and MCP-1 in the culture supernatant of the experimental group compared to the control group was observed by ELISA. The applicant thus assumes that: high expression of TSLP can facilitate the resorption process.
The invention researches the effect of TSLP expression on reabsorption of lumbar disc tissues and provides the application of TSLP in preparing a medicament for treating lumbar disc herniation.
Further, high expression of TSLP can promote resorption of the herniated lumbar disc tissue.
Compared with the prior art, the invention has the beneficial effects that: the invention provides that the high expression of TSLP can promote the reabsorption of the tissues of the herniated lumbar disc. The application of the compound in preparing the medicine for treating the lumbar disc herniation provides a new molecular theoretical basis for researching the pathophysiological process of the lumbar disc herniation in the future, and provides a new target for seeking the best anti-inflammatory time and conservatively treating the lumbar disc herniation by utilizing an organism autogenous repair mechanism in the future.
Drawings
FIG. 1 is a drawing of a rat nucleus pulposus cell culture at 2X magnification and at 4X magnification.
FIG. 2 is a graph showing the identification of nucleus pulposus cells by immunofluorescence assay, wherein A is the Collagen II stain (200-fold), B is the nuclear stain (200-fold), C is the Collagen II stain (400-fold), and D is the nuclear stain (400-fold).
FIG. 3 is a graph showing the phosphorylation levels of NF-. kappa.B in tissues detected by immunohistochemistry, showing positive nuclear staining in the brown-yellow or brown-brown color, and the ABC method x40, in which A is a control group, B is a TNF-. alpha.group, C is a TGF-. beta.group, and D is a TGF-. beta.inhibitor group (HTS group).
FIG. 4 shows the expression of p-NF-. kappa.B protein detected by immunoblotting (Western-blot) after culturing mouse intervertebral disc tissues for 0, 3, 6, 12 and 24 hours using 10ng/ml TNF-. alpha.10 ng/ml TGF-. beta.and 1uM HTS (TGF-. beta.pathway inhibitor).
FIG. 5 is a graph showing the detection of the expression of each gene by qRT-PCR technique under the action of IL-6 and JAK/STAT inhibitors (BP-1-102). A is the expression of JAK1, STAT3 and TSLP mRNA under the stimulation of IL-6(10 ng/ml); b is the expression of STAT3, TSLP mRNA under the action of JAK/STAT inhibitor (BP-1-102,500 nM). (represents P <0.05, represents P <0.01, represents P <0.001)
FIG. 6 is a graph showing the expression of TSLP protein detected by Western-blot technique under the action of IL-6 and JAK/STAT inhibitor (BP-1-102).
FIG. 7 is a graph showing the expression of TGF-. beta.in cell culture supernatants 72h after the action of IL-6, TGF-. beta./SMAD pathway inhibitor, JAK/STAT pathway inhibitor. (represents P <0.05)
Detailed Description
The technical scheme of the invention is further described in detail by combining the drawings and the detailed implementation mode:
first, main material and reagent
DMEM/F12, trypsin, fetal bovine serum (Gibico, USA); trizol (Ambion, USA); reverse transcription kit (term, USA) qPCR kit (KAPA, switzerland); collagenase type II (biofvexx, sweden); mouse anti-Smad 2, rabbit anti-Smad 7, mouse anti-p-STAT 3, rabbit anti-TSLP, HRP labeled secondary antibody (Shanghai Biotechnology engineering Co., Ltd., Shanghai, China); flasks, plates (NEST, Thermo, USA).
Second, separation and culture of rat nucleus pulposus cells
4-week-old female SD rats (provided by the animal testing center of Sigan university of transportation) were sacrificed by intraperitoneal overdose with anesthetic and soaked in 75% ethanol for 10 min. Separating the spine along the back on an aseptic experiment table, stripping the attached tissues around the spine, washing with aseptic PBS for 3 times, separating the intervertebral disc under a microscope (keeping the upper and lower end plates), cutting open the fibrous ring, carefully collecting the jelly-like nucleus pulposus tissue to a 1.5ml centrifuge tube, cleaning the collected nucleus pulposus tissue with PBS liquid containing antibiotics and antibiotics for 3 times, centrifuging at 1500rpm for 5min, and discarding the supernatant; adding 0.25% pancreatin, digesting at 37 deg.C for 30min, shaking once every 15min, stopping digestion with DMEM containing serum, centrifuging at 1000rpm for 5min, and removing supernatant; using DMEM/F12 (20% FPS, double antibody) culture medium containing 0.2% type II collagenase for heavy suspension, standing and digesting for 4h at 37 ℃, shaking once every 1h, filtering by using a 70um cell filter screen after the flocculent tissue disappears, centrifuging at 900rpm of filtrate for 5min, and discarding the supernatant; DMEM/F12 (20% FPS, double antibody) was resuspended, inoculated into a 25cm2 air-permeable flask, and placed in a CO2 incubator at 37 ℃ with saturated humidity and 5% volume fraction. The first fluid change was performed after 5 days, and the fluid change was performed every 2 days thereafter. Cell attachment and growth were observed under a microscope as shown in FIG. 1. When the rate of the rat nucleus pulposus cell adnexal growth fusion reaches 80%, subculturing the cells. The cells were washed twice with PBS, the supernatant was discarded, and the cells were digested with 0.25% trypsin. Observing under microscope, digesting for 1-2min to see that cells are separated from each other and become round, i.e. digestion is completed. Rapidly removing pancreatin, adding complete culture medium, blowing to make cells, preparing single cell suspension, subculturing according to the proportion of 1:4, carrying out amplification culture at 37 ℃ under the condition of 5% CO2 saturated humidity, and taking the nucleus pulposus cells of the second and third generations of rats for subsequent tests.
Thirdly, identifying nucleus pulposus cells by immunofluorescence labeling
Cultured rat nucleus pulposus cells in logarithmic growth phase are digested by 0.25% trypsin, collected in a 1.5ml EP tube, and after acidification treatment of a sterile slide, the cells are dropped on the slide. The cells were cultured in a 5% CO2 incubator at 37 ℃. When the cell wall attachment fusion rate reaches 80%, the slide is taken out, and the supernatant is discarded. PBS was used for 3 dips for 3min each. The slides were washed 3 times with PBS again after 15 minutes, 3min each time, using 4% paraformaldehyde drop wise. Excess paraformaldehyde is washed away. 0.5% Triton X-100 (in PBS) was allowed to permeate for 20min at room temperature. The slides were washed 3 times with PBS for 3min each time. And (3) sucking the redundant PBS by using absorbent paper, dripping the prepared normal goat serum on the slide, and sealing the slide at room temperature after the completion. After 30min, the blocking solution was again sucked off with absorbent paper, and without rinsing, a sufficient amount of rabbit anti-mouse type II collagen antibody and polyprotein antibody (1: 100) was again added dropwise to each slide and placed in a wet box and incubated overnight at 4 ℃. The next day, the slides were rinsed 3 times with PBS, 3min each time. The excess PBS on the slide was blotted dry with absorbent paper, and diluted fluorescent (Cy3) -labeled goat anti-rabbit IgG (1: 100) was dropped onto the slide, and all subsequent processing steps were transferred to the dark room from the addition of the fluorescent secondary antibody. The slide added with the secondary antibody is placed in a wet box and incubated for 1h at the temperature of 20-37 ℃. After being taken out, the glass slide is soaked and washed by PBS for 3 times, each time for 3min, and DAPI is dripped to stain the core of the specimen. After incubation in the dark for 5min, the slides were rinsed with PBS for 6 times, 5min each time, and excess DAPI was washed off; after completion, excess liquid on the slide was blotted with absorbent paper. Mounting the slide with mounting solution containing an anti-fluorescence quencher, and then observing the prepared slide under a fluorescence microscope and collecting an image, as shown in FIG. 2.
Fourthly, extracting the rat intervertebral disc tissue protein by freezing and grinding
4-week-old female SD rats (provided by the animal testing center of Sigan university of transportation) were sacrificed by intraperitoneal overdose with anesthetic and soaked in 75% ethanol for 10 min. Separating spine along back on sterile experiment table, stripping attached tissue around spine, washing with sterile PBS for 3 times, separating intervertebral disc under microscope, and performing sterile operation. The intervertebral discs are separated, washed 3 times by using DMEM containing double antibody, and inoculated in a 24-hole plate respectively, 1 intervertebral disc tissue per hole is added with DMEM containing IL-6(10ng/ml), TGF-beta pathway inhibitor (SB431542,150ng/ml) and JAK/STAT pathway inhibitor (BP-1-102,500ng/ml), cultured for 72 hours at 37 ℃ with 5% CO2, the tissues are cut into 1mm3 size by an ophthalmic scissors, 0.1g of tissues are weighed and placed in a sterilization mortar, 10ml of liquid nitrogen is added for rapid rotary grinding to be powdery, 150ul of cell lysate containing 1% protease inhibitor (PMSF) is added for fully cracking the cells (whole ice operation), centrifugation is carried out for 5min at 4 ℃ and 12000rpm, the protein concentration is determined by a BCA method, and the extracted protein is used for Western Blot test.
Fifthly, real-time fluorescent quantitative PCR (qRT-PCR)
Adjusting cell number to 2.5X 105Cells/ml, seeded in 6-well plates at 37 ℃ with 5% CO2Culturing for 12h to 70%, adding IL-6(10ng/ml), TGF-beta pathway inhibitor (SB431542,150ng/ml), JAK/STAT pathway inhibitor (BP-1-102,500ng/ml), and alpha-MEM at 37 deg.C for control group, and 5% CO2After culturing for 72h, mRNA is extracted by using a Trizol method, and the expression of JAK1, JAK2, STAT3, SMAD2/3/7 and TSLP mRNA is detected by using a qRT-PCR technology. The primers were synthesized by Beijing Optimalaceae New Biotechnology Co., Ltd (see Table 1 for primer sequences). The specific conditions are as follows: 95 ℃, 3min, 1 cycle; 40 cycles of 95 deg.C, 3s and 60 deg.C, 20s, using non-reagentDissociation curve determination by the anisotropic amplification method.
Sixth, the immunity mark test (Western-Blot)
Adjusting cell number to 2.5X 105Cells/ml, seeded in 6-well plates at 37 ℃ with 5% CO2Culturing for 12h to 70%, adding IL-6(10ng/ml) and TGF-beta pathway inhibitor (SB431542,150ng/ml) respectively, JAK/STAT pathway inhibitor (BP-1-102,500ng/ml) was cultured for 72 hours at 37 ℃ in 5% CO2, washed 3 times with PBS, cells were sufficiently lysed by adding cell lysate containing 1% protease inhibitor (PMSF) (whole procedure on ice), centrifuged at 12000rpm for 5 minutes at 4 ℃, separated on 10% SDS-polyacrylamide gel (SDS-PAGE) for 1 hour, wet-transferred to polyvinylidene fluoride membrane (PVDF membrane) for 1.5 hours, 5% skim milk powder was blocked at room temperature for 1 hour, primary antibody was added, incubated overnight at 4 ℃, washed 3 times with Tris-HCl buffer salt solution (TBST), incubated with HRP-labeled secondary antibody at room temperature for 1 hour, washed 3 times with TBST for 5 minutes each, and photographed by exposure.
Enzyme-linked immunosorbent assay (ELISA)
The supernatant of the 72-hour cell culture was collected, 100ul of the supernatant of IL-6(10ng/ml), TGF- β pathway inhibitor (SB431542,150ng/ml), JAK/STAT pathway inhibitor (BP-1-102,500ng/ml) was added to each well of the polystyrene plate, and the plate was kept at 4 ℃ overnight in the dark. The next day, incubation in the dark at 37 ℃ for 1h, discarding the supernatant, washing with 1% TBST for 3 times, 3min each time, adding primary antibody, incubation in the dark at 37 ℃ for 1h, washing with TBST for 3 times, adding secondary antibody, incubation in the dark at 37 ℃ for 1h, adding color-developing agent in the dark, developing at 37 ℃ for 30min, adding terminator and detecting the OD 450nm value on a spectrophotometer.
Statistical analysis
The database was built using Excel statistical software (Microsoft, USA) and statistical analysis was performed. The two groups of mean comparisons were tested with independent samples t, and differences of P <0.05 were statistically significant.
Analysis of results
One, the IL-6 mediated JAK/STAT signaling pathway promotes the resorption process of herniated disc tissue by modulating expression of TSLP.
Expression of JAK/STAT pathway-associated factors JAK1, STAT3, and TSLP mRNA following treatment of rat MSCs with IL-6, JAK/STAT pathway inhibitors (BP-1-102), respectively (see FIG. 5). IL-6 stimulation upregulates the expression of JAK1, STAT3, TSLP mRNA in rat cells. While STAT3, TSLP expression was significantly reduced in the presence of inhibition of the JAK/STAT pathway (BP-1-102). In terms of protein expression, a significant increase in TSLP protein expression was also observed with IL-6 stimulation using the immunoblot assay (Western-blot), whereas in the presence of JAK/STAT inhibitors, TSLP protein expression was significantly reduced (see FIG. 6). This suggests that the IL-6 mediated JAK/STAT signaling pathway is involved in the resorption process of herniated disc tissue by upregulating TSLP expression.
Secondly, the endogenous TGF-beta has the inhibition effect on the NF-kappa B pathway
Previous experiments of the applicant found that after rat intervertebral disc tissues are co-cultured with 10ng/ml TNF-alpha, 10ng/ml TGF-beta and 1uMHTS (TGF-beta pathway inhibitor) for 6 hours, the phosphorylation level of NF-kappa B in the tissues is detected by using an immunohistochemistry method, and the staining of cell nucleus is positive to brown or brown, and the result shows that: the TNF-alpha group had the highest number of positive cells, followed by the TGF-beta inhibitor group (HTS group), while only a few positive cells were seen in the TGF-beta group and the control group, as shown in FIG. 3. Only a small amount of phosphorylated NF-kappa B positive cells, 9.4% + -3.3%, were seen in the control group; the most phosphorylated NF-kappa B positive cells of the BTNF-alpha group are 92.4% +/-1.4%; the TGF-beta group expresses a small number of phosphorylated NK-kappa B positive cells which are 33.7% +/-8.8%; the number of positive cells in the TGF-. beta.inhibitor group (HTS group) was 74.1%. + -. 6.7% second only in the TNF-. alpha.group.
The differences in each group were statistically significant (F: 167.669, P: 0.000); any two groups of comparison differences were statistically significant (mean P ═ 0.000).
Murine intervertebral disc tissue was co-cultured with 10ng/ml TNF-. alpha.10 ng/ml TGF-. beta.1 uM HTS (TGF-. beta.pathway inhibitor) for 0, 3, 6, 12, 24h, then histones were extracted by cryomilling and the expression of phosphorylated NF-. kappa.B protein was detected using immunoblot assay (Western-blot), as shown in FIG. 4: after 3 and 6 hours of culture, compared with a control group, the expression of phosphorylated NF-kappa B protein is obviously increased in a TNF-alpha group and a TGF-beta inhibitor group (HTS group), which indicates that endogenous TGF-beta can inhibit the phosphorylation of NF-kappa B.
The results show that after 3 and 6 hours of culture, the expression of phosphorylated NF-kB is obviously increased in a TGF-beta inhibitor group (HTS group) and a TNF-alpha group compared with a control group, and the inhibition of the activity of TGF-beta (HTS group) and the TNF-alpha group have the effect of inducing the expression of phosphorylated NF-kB protein.
And thirdly, the influence of IL-6 on the expression of TGF-beta in nucleus pulposus cells of rats.
Rat nucleus pulposus cells were cultured by using IL-6(10ng/ml), TGF-beta pathway inhibitor (SB431542,150ng/ml) and JAK/STAT pathway inhibitor (BP-1-102,500ng/ml), respectively, and cell culture supernatants were collected at 72 hours, and the TGF-beta concentration in the supernatants was measured by enzyme-linked immunosorbent assay (ELISA), and the results showed that: under IL-6 stimulation, the TGF-beta concentration in the cell culture supernatant was increased, and the TGF-beta pathway inhibitor group and the JAK/STAT pathway inhibitor group were decreased compared with the control group (see FIG. 7).
Compared with the control group, the concentration of TGF-beta in the cell culture supernatant fluid is increased under the stimulation of IL-6; a decrease in TGF-. beta.concentration in the supernatant was observed following inhibition of the TGF-. beta.and JAK/STAT pathways.
Conclusion of the experiment
First, IL-6 regulates the expression of TSLP through the JAK/STAT signal pathway and participates in the reabsorption of herniated disc tissue.
Studies have shown that TSLP can promote infiltration of macrophages into disc tissue by inducing increased expression of monocyte chemotactic factor-1 (MCP-1), thereby promoting the resorption process of herniated disc tissue. In the experiment, the applicant observes that JAK1, STAT3 and TSLP mRNA is in a high expression state after exogenous IL-6 stimulation is added for 72 hours, and the expression of JAK/STAT pathway key factors STAT3 and TSLP mRNA is obviously reduced after JAK/STAT pathway inhibitor (BP-1-102) is added. Immunoblotting experiments also demonstrated a significant increase in TSLP protein expression following stimulation with added IL-6. This suggests that IL-6 induces an increase in expression of TSLP through the JAK/STAT signaling pathway, and is involved in the resorption process of disc herniation.
And secondly, IL-6 influences the activity of a TGF-beta signal channel through a JAK/STAT signal channel, thereby influencing the expression of TSLP and further participating in the reabsorption process of the intervertebral disc protrusion.
Applicants' studies demonstrate that under physiological conditions the TGF- β signaling pathway in disc tissue assumes a certain activation state and inhibits TSLP expression. In this experiment, the applicant observed that the mRNA expression of Smad2, a TGF-beta pathway marker, was significantly increased after IL-6 stimulation, while the expression of Smad2 was significantly decreased after JAK/STAT pathway inhibitor addition (BP-1-102), and the immunoblot assay (Western-blot) also showed a significant increase in Smad2 protein expression after IL-6 addition. At the same time, we observed an increase in TGF- β concentration in cell culture supernatants after IL-6 addition (P <0.05) and a decrease in TGF- β concentration in supernatants after JAK/STAT pathway inhibition (P <0.05) in enzyme-linked immunosorbent assays (ELISA). It follows that under IL-6 stimulation, the JAK/STAT signaling pathway is activated, which in turn leads to activation of the TGF- β pathway.
Under normal physiological conditions, TSLP expression continues to be inhibited, and this inhibition is caused by the continuous, minimal expression of TGF- β by disc tissue. When the lumbar disc herniates, this inhibition is broken, TSLP expression is elevated, which in turn elevates MCP-1 expression, which can induce macrophage infiltration into the herniated disc tissue, causing and promoting the resorption process. In the experiment, the applicant finds that the inflammatory factor IL-6 can activate JAK/STAT pathway to up-regulate TSLP expression, which provides a new thought for researching inflammation generation and reabsorption mechanism of the lumbar intervertebral disc protrusion and a new target for conservative treatment of the lumbar intervertebral disc protrusion. In addition, the IL-6/JAK/STAT family affects the TGF-. beta./Smads family, suggesting a potentially important role for IL-6 in maintaining disc local microenvironment homeostasis.
The above description is only an embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that are not thought of through the inventive work should be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope defined by the claims.
Sequence listing
<110> second subsidiary hospital of inner Mongolia medical university
Application of <120> TSLP in preparation of medicine for treating lumbar disc herniation
<160>12
<170>SIPOSequenceListing 1.0
<210>1
<211>24
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
gtgatgaata acgaccacca aaat 24
<210>2
<211>22
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
tcctactagg gagcagggat ag 22
<210>3
<211>21
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
cacccatagt gagcccttgg a 21
<210>4
<211>22
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
tgagtgcagt gaccaggaca ga 22
<210>5
<211>20
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
ttcatctgaa tggccccctg 20
<210>6
<211>20
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
ccaatgagct ccactgctga 20
<210>7
<211>25
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
atatgatgcg gatttttggt tgtgt 25
<210>8
<211>23
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
tgactcttgc ttcccgtttt tgt 23
<210>9
<211>20
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>9
tcctgaaaat cgaccaccat 20
<210>10
<211>20
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>10
aatgcaggaa agccacaatc 20
<210>11
<211>19
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>11
ggctacagct tcaccacca 19
<210>12
<211>19
<212>DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400>12
tgctgatcca catctgctg 19
Claims (2)
- The application of TSLP in preparing medicine for treating protrusion of lumbar vertebral disc.
- 2. The use of a TSLP as claimed in claim 1 in the manufacture of a medicament for the treatment of lumbar disc herniation, wherein high expression of TSLP promotes resorption of herniated lumbar disc tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911016907.6A CN110680905A (en) | 2019-10-24 | 2019-10-24 | Application of TSLP in preparation of medicine for treating lumbar disc herniation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911016907.6A CN110680905A (en) | 2019-10-24 | 2019-10-24 | Application of TSLP in preparation of medicine for treating lumbar disc herniation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110680905A true CN110680905A (en) | 2020-01-14 |
Family
ID=69114367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911016907.6A Pending CN110680905A (en) | 2019-10-24 | 2019-10-24 | Application of TSLP in preparation of medicine for treating lumbar disc herniation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110680905A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110091463A1 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN103025758A (en) * | 2010-05-14 | 2013-04-03 | Abbvie公司 | IL-1 binding proteins |
| CN104203278A (en) * | 2011-11-21 | 2014-12-10 | 阿布维公司 | IL-1 binding proteins |
| CN105400894A (en) * | 2015-12-24 | 2016-03-16 | 北京泱深生物信息技术有限公司 | Intervertebral disc degenerative change diagnosis and treatment marker |
| JP2017081870A (en) * | 2015-10-30 | 2017-05-18 | 学校法人慶應義塾 | JAK-STAT3 inhibitor for the treatment of intervertebral disc degeneration |
| CN106947808A (en) * | 2017-03-10 | 2017-07-14 | 北京赛尔得生物技术有限公司 | Application of the TMEM104 genes in treatment Degenerative disc disease medicine is prepared |
-
2019
- 2019-10-24 CN CN201911016907.6A patent/CN110680905A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110091463A1 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN103025758A (en) * | 2010-05-14 | 2013-04-03 | Abbvie公司 | IL-1 binding proteins |
| CN104203278A (en) * | 2011-11-21 | 2014-12-10 | 阿布维公司 | IL-1 binding proteins |
| JP2017081870A (en) * | 2015-10-30 | 2017-05-18 | 学校法人慶應義塾 | JAK-STAT3 inhibitor for the treatment of intervertebral disc degeneration |
| CN105400894A (en) * | 2015-12-24 | 2016-03-16 | 北京泱深生物信息技术有限公司 | Intervertebral disc degenerative change diagnosis and treatment marker |
| CN106947808A (en) * | 2017-03-10 | 2017-07-14 | 北京赛尔得生物技术有限公司 | Application of the TMEM104 genes in treatment Degenerative disc disease medicine is prepared |
Non-Patent Citations (5)
| Title |
|---|
| TETSURO OHBA ET AL: "A Potential Role of Thymic Stromal Lymphopoietin in the Recruitment of Macrophages to Mouse Intervertebral Disc Cells via Monocyte Chemotactic Protein 1 Induction(Implications for Herniated Discs)", 《ARTHRITIS & RHEUMATISM》 * |
| YONG ZHU ET AL: "Endogenous TGF-β activity limits TSLP expression in the intervertebral disc tissue by suppressing NF-κB activation", 《JOURNAL OF ORTHOPAEDIC RESEARCH》 * |
| 卞泗善 等主编: "《现代骨病与骨伤诊疗进展》", 30 June 2018, 上海交通大学出版社 * |
| 朱宇等: "腰椎间盘突出后重吸收的研究进展", 《中国脊柱脊髓杂志》 * |
| 陈华等: "生物活性因子治疗椎间盘退变性疾病的研究进展", 《华西医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Pre-vascularization enhances therapeutic effects of human mesenchymal stem cell sheets in full thickness skin wound repair | |
| Tang et al. | Masquelet’s induced membrane promotes the osteogenic differentiation of bone marrow mesenchymal stem cells by activating the Smad and MAPK pathways | |
| Yu et al. | Human nail bed extracellular matrix facilitates bone regeneration via macrophage polarization mediated by the JAK2/STAT3 pathway | |
| He et al. | Optimized adipose tissue engineering strategy based on a neo‐mechanical processing method | |
| Liu et al. | Semaphorin 3A shifts adipose mesenchymal stem cells towards osteogenic phenotype and promotes bone regeneration in vivo | |
| CN109847098B (en) | A composite bioscaffold material for repairing bone defects | |
| Cai et al. | Identification of the CXCL12–CXCR4/CXCR7 axis as a potential therapeutic target for immunomodulating macrophage polarization and foreign body response to implanted biomaterials | |
| CN102373175B (en) | Application of raloxifene in mesenchymal stem cell in-vitro osteoblast differentiation | |
| CN110680905A (en) | Application of TSLP in preparation of medicine for treating lumbar disc herniation | |
| CN110585423A (en) | Application of IL-6 in preparation of medicine for treating lumbar disc herniation | |
| CN116426469B (en) | Application of LAP2 alpha in mesenchymal stem cell adipogenic differentiation | |
| Fang et al. | Inhibition of peritendinous adhesion through targeting JAK2-STAT3 signaling pathway: the therapeutic potential of AG490 | |
| KR101219624B1 (en) | Treating tissue damage or enhancing tissue repair, pharmaceutical composition | |
| CN119367513A (en) | Application of neuropeptide S in promoting EMSCs to treat spinal cord injury | |
| CN110613837A (en) | Application of TGF-beta in preparation of medicine for preventing or treating lumbar disc herniation | |
| CN116396935A (en) | M2 type macrophage exosome and application thereof | |
| CN113925972B (en) | Application of OTUB1 protein in treating osteoporosis | |
| CN112126621A (en) | Application of AMPK activator in preparation of product for improving AMPK signal pathway abnormity in mesenchymal stem cells | |
| Yang et al. | One-step stromal vascular fraction therapy in osteoarthritis with tropoelastin-enhanced autologous stromal vascular fraction gel | |
| US12139725B2 (en) | Composition for promoting stem cell differentiation, comprising progenitor cell culture solution and multilayer graphene film, and use thereof | |
| Wang et al. | Large conductance voltage and Ca2+-activated K+ channels affect the physiological characteristics of human urine-derived stem cells | |
| CN119139293B (en) | Gemmaalkane sesquiterpenes use of lactones | |
| US9233128B2 (en) | Use of cryptotanshinone | |
| EP4461807A1 (en) | Cell culture sheet for treating liver dysfunction | |
| CN121265779A (en) | Immunotherapy strategies targeting IL-18 or its downstream pathways to improve bone tissue repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200114 |
|
| RJ01 | Rejection of invention patent application after publication |